While some researchers still claim that embryonic stem cells (ESCs) offer the best hope for treating many debilitating diseases, there is now a great deal of evidence contrary to that theory. Use of stem cells obtained by destroying human embryos is not only unethical but presents many practical obstacles as well.
"Major roadblocks remain before human embryonic stem cells could be transplanted into humans to cure diseases or replace injured body parts, a research pioneer said Thursday night. University of Wisconsin scientist James Thomson said obstacles include learning how to grow the cells into all types of organs and tissue and then making sure cancer and other defects are not introduced during the transplantation. 'I don't want to sound too pessimistic because this is all doable, but it's going to be very hard,' Thomson told the Wisconsin Newspaper Association's annual convention at the Kalahari Resort in this Wisconsin Dells town. 'Ultimately, those transplation therapies should work but it's likely to take a long time.'....Thomson cautioned such breakthroughs are likely decades away."
-Associated Press reporter Ryan J. Foley "Stem cell pioneer warns of roadblocks before cures," San Jose Mercury News Online, posted on Feb. 8, 2007, http://www.mercurynews.com/mld/mercurynews/16656570.htm
"Although embryonic stem cells have the broadest differentiation potential, their use for cellular therapeutics is excluded for several reasons: the uncontrollable development of teratomas in a syngeneic transplantation model, imprinting-related developmental abnormalities, and ethical issues."
-Gesine Kgler et al., "A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential," Journal of Experimental Medicine, Vol. 200, No. 2 (July 19, 2004), p. 123.
From a major foundation promoting research in pancreatic islet cells and other avenues for curing juvenile diabetes:
"Is the use of embryonic stem cells close to being used to provide a supply of islet cells for transplantation into humans?
"No. The field of embryonic stem cells faces enormous hurtles to overcome before these cells can be used in humans. The two key challenges to overcome are making the stem cells differentiate into specific viable cells consistently, and controlling against unchecked cell division once transplanted. Solid data of stable, functioning islet cells from embryonic stems cells in animals has not been seen."
-"Q & A," Autoimmune Disease Research Foundation, http://www.cureautoimmunity.org/Q%20&%20A.htm, accessed July 2004.
"'I think the chance of doing repairs to Alzheimer's brains by putting in stem cells is small,' said stem cell researcher Michael Shelanski, co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at the Columbia University Medical Center in New York, echoing many other experts. 'I personally think we're going to get other therapies for Alzheimer's a lot sooner.'...
"[G]iven the lack of any serious suggestion that stem cells themselves have practical potential to treat Alzheimer's, the Reagan-inspired tidal wave of enthusiasm stands as an example of how easily a modest line of scientific inquiry can grow in the public mind to mythological proportions.
"It is a distortion that some admit is not being aggressively corrected by scientists.
"'To start with, people need a fairy tale,' said Ronald D.G. McKay, a stem cell researcher at the National Institute of Neurological Disorders and Stroke. 'Maybe that's unfair, but they need a story line that's relatively simple to understand.'"
-Rick Weiss, "Stem Cells an Unlikely Therapy for Alzheimer's," Washington Post, June 10, 2004, p. A3.
"ES [embryonic stem] cells and their derivatives carry the same likelihood of immune rejection as a transplanted organ because, like all cells, they carry the surface proteins, or antigens, by which the immune system recognizes invaders. Hundreds of combinations of different types of antigens are possible, meaning that hundreds of thousands of ES cell lines might be needed to establish a bank of cells with immune matches for most potential patients. Creating that many lines could require millions of discarded embryos from IVF clinics."
-R. Lanza and N. Rosenthal, "The Stem Cell Challenge," Scientific American, June 2004, pp. 92-99 at p. 94. [Editor's note: A recent study found that only 11,000 frozen embryos are available for research use from all the fertility clinics in the U.S., and that destroying all these embryos for their stem cells might produce a total of 275 cell lines. See Fertility and Sterility, May 2003, pp. 1063-9 at p. 1068.]
"Embryonic stem cells have too many limitations, including immune rejection and the potential to form tumors, to ever achieve acceptance in our lifetime. By that time, umbilical cord blood stem cells will have been shown to be a true 'gift from the gods.'"
-Dr. Roger Markwald, Professor and Chair of Cell Biology and Anatomy at the Medical University of South Carolina, quoted in "CureSource Issues Statement on Umbilical Cord Blood Stem Cells vs. Embryonic Stem Cells," BusinessWire, May 12, 2004, also at http://curesource.net/why.html.
"'We're not against stem-cell research of any kind,' said [Tulane University research professor Brian] Butcher. 'But we think there are advantages to using adult stem cells. For example, with embryonic stem cells, a significant number become cancer cells, so the cure could be worse than the disease. And they can be very difficult to grow, while adult stem cells are easy to grow.'"
-Heather Heilman, "Great Transformations," The Tulanian (Spring 2004 issue), at http://www2.tulane.edu/article_news_details.cfm?ArticleID=5155.
"There are still many hurdles to clear before embryonic stem cells can be used therapeutically. For example, because undifferentiated embryonic stem cells can form tumors after transplantation in histocompatible animals, it is important to determine an appropriate state of differentiation before transplantation. Differentiation protocols for many cell types have yet to be established. Targeting the differentiated cells to the appropriate organ and the appropriate part of the organ is also a challenge."
-E. Phimister and J. Drazen, "Two Fillips for Human Embryonic Stem Cells," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1351-2 at 1351.
Harvard researchers, trying to create human embryonic stem cell lines that are more clinically useful than those now available, find that their new cell lines are already genetically abnormal:
"After prolonged culture, we observed karyotypic changes involving trisomy of chromosome 12..., as well as other changes... These karyotypic abnormalities are accompanied by a proliferative advantage and a noticeable shortening in the population doubling time. Chromosomal abnormalities are commonplace in human embryonal carcinoma cell lines and in mouse embryonic stem-cell lines and have recently been reported in human embryonic stem-cell lines."
-C. Cowan et al., "Derivation of Embryonic Stem-Cell Lines from Human Blastocysts," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1353-6 at 1355.
"[Johns Hopkins University] biologist Michael Shamblott said...major scientific hurdles await anybody wishing to offer a treatment, let alone a cure, based on cells culled from embryos.
"Among the major obstacles is the difficulty of getting embryonic stem cells master cells that generate every tissue in the human body to become exactly the type of cell one wants... Scientists...haven't been able to guarantee purity cells, for instance, that are destined to become muscle cells and nothing else...
"Transplanting a mixed population of cells could cause the growth of unwanted tissues. The worst case could see stem cells morphing into teratomas, particularly gruesome tumors that can contain hair, teeth and other body parts.
"Another issue is timing... Stem cells pass through many intermediate stages before they become intermediate cells such as motor neurons or pancreatic or heart cells. Deciding when to transplant remains an open question, and the answer might differ from disease to disease.
"...In tackling Lou Gehrig's disease, [Johns Hopkins neurologist Dr. Jeffrey] Rothstein figured that cells that haven't committed themselves to becoming motor neurons would stand the best chance, once implanted, of reaching out and connecting with the cells that surround them. What he found, however, is that these immature cells didn't develop much once transplanted into lab animals."
-Jonathan Bor, "Stem Cells: A long road ahead," Baltimore Sun, March 8, 2004, p. 12A.
"Tony Blau, a stem-cell researcher at the University of Washington, said it is 'extremely laborious' to keep embryonic cells growing, well-nourished and stable in the lab so they don't die or turn into a cell type with less potential. Researchers need to know how to channel the stem cells to create a specific kind of cell, how to test whether they're pure, and how to develop drugs that could serve as a sort of antidote in case infused stem cells started creating something dangerous, such as cancer.
"Big companies, Blau said, want to know that their drugs will be almost completely stable, standard, pure and consistent, because they can behave differently if they aren't. Stem cells never will achieve that kind of standardization, Blau said, because living cells are more complex than chemically synthesized drugs."
-Luke Timmerman, "Stem-cell research still an embryonic business," Seattle Times, Business & Technology section, February 22, 2004, at http://seattletimes.nwsource.com/html/businesstechnology/2001862747_stemcells22.html.
"[W]ithin the ESC research community, realism has overtaken early euphoria as scientists realize the difficulty of harnessing ESCs safely and effectively for clinical applications. After earlier papers in 2000 and 2001 identified some possibilities, research continued to highlight the tasks that lie ahead in steering cell differentiation and avoiding side effects, such as immune rejection and tumorigenesis."
-Philip Hunter, "Differentiating Hope from Embryonic Stem Cells," The Scientist, Vol. 17, Issue 34 (December 15, 2003), at http://www.the-scientist.com/yr2003/dec/hot_031215.html.
"Long-term culture of mouse ES [embryonic stem] cells can lead to a decrease in pluripotency and the gain of distinct chromosomal abnormalities. Here we show that similar chromosomal changes, which resemble those observed in hEC [human embryonal carcinoma] cells from testicular cancer, can occur in hES [human embryonic stem] cells.... The occurrence and potential detrimental effects of such karyotopic changes will need to be considered in the development of hES cell-based transplantation therapies."
-J. Draper et al., "Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells," Nature Biotechnology, Vol. 22 (2003), pp. 53-4.
"James A. Thompson of the University of Wisconsin, Madison, and his colleagues managed to isolate and culture the first human embryonic stem cells in 1997. Five years later, big scientific questions remain. [Harvard embryonic stem cell researcher Doug] Melton and his colleagues, for instance, don't yet know how to instruct the totipotent stem cells to become the specific cells missing in a diabetic person, the pancreatic beta cell.
"'Normally, if you take an embryonic stem cell, it will make all kinds of things, sort of willy-nilly,' says Melton."
-J. Mitchell, "Stem Cells 101," PBS Scientific American Frontiers, May 28, 2002, http://www.pbs.org/saf/1209/features/stemcell.htm.
"Unlike stem cells isolated from the embryo, [adult stem cells] do not carry the same risks of cancer or uncontrollable growth after transplant, and they can be isolated from patients requiring treatment, thus avoiding all problems of immune rejection and the need for immune suppressive drugs that carry their own risks.
"...Embryonic stem cells are promoted on grounds that they are developmentally more flexible than adult stem cells. But too much flexibility may not be desirable. Transplant of embryonic cells into the brains of Parkinson's patients turned into an irredeemable nightmare because the cells grew uncontrollably. Embryonic stem cells also show genetic instability and carry considerable risks of cancer... When injected under the skin of certain mice, they grow into teratomas, tumors consisting of a jumble of tissue types, from gut to skin to teeth, and the same happens when injected into the brain."
-Dr. Mae-Wan Ho and Prof. Joe Cummins on behalf of the Institute of Science in Society (ISIS), "Hushing Up Adult Stem Cells," ISIS report, February 11, 2002, at http://www.i-sis.org.uk/HUASC.php.
"'I even hear from patients whose fathers have lung cancer,' said Dr. Hogan, a professor at Vanderbilt School of Medicine. 'They have a whole slew of problems they think can be treated. They think stem cells are going to cure their loved ones of everything.'
"If it ever happens, it will not happen soon, scientists say. In fact, although they worked with mouse embryonic stem cells for 20 years and made some progress, researchers have not used these cells to cure a single mouse of a disease...
"Scientists say the theory behind stem cells is correct: the cells, in principle, can become any specialized cell of the body. But between theory and therapy lie a host of research obstacles...the obstacles are so serious that scientists say they foresee years, if not decades, of concerted work on basic science before they can even think of trying to treat a patient."
-Gina Kolata, "A Thick Line Between Theory and Therapy, as Shown with Mice," New York Times, December 18, 2001, p. F3.
"Mice cloned from embryonic stem cells may look identical, but many of them actually differ from one another by harboring unique genetic abnormalities, scientists have learned...
"The work also shows for the first time that embryonic stem cells...are surprisingly genetically unstable, at least in mice. If the same is true for human embryonic stem cells, researchers said, then scientists may face unexpected challenges as they try to turn the controversial cells into treatments for various degenerative conditions."
-Rick Weiss, "Clone Study Casts Doubt on Stem Cells," Washington Post, July 6, 2001, p. A1.
"ES cells have plenty of limitations... For one, murine ES cells have a disturbing ability to form tumors, and researchers aren't yet sure how to counteract that. And so far reports of pure cell populations derived from either human or mouse ES cells are few and far between fewer than those from adult stem cells."
-Gretchen Vogel, "Can Adult Stem Cells Suffice?", Science, Vol. 292 (June 8, 2001), pp. 1820-1822 at 1822.
"Rarely have specific growth factors or culture conditions led to establishment of cultures containing a single cell type.... [T]he possibility arises that transplantation of differentiated human ES cell derivatives into human recipients may result in the formation of ES cell-derived tumors... Irrespective of the persistence of stem cells, the possibility for malignant transformation of the derivatives will also need to be addressed."
-J. S. Odorico et al, "Multilineage differentiation from human embryonic stem cell lines," Stem Cells Vol. 19 (2001), pp. 193-204 at 198 and 200, at http://stemcells.alphamedpress.org/cgi/reprint/19/3/193.pdf.
Read the original post:
Practical Problems with Embryonic Stem Cells - usccb.org
- How Will Animals Get Benefitted by Stem Cell Therapy? - Medical Tech Outlook - December 13th, 2019
- 14 Advantages and Disadvantages of Embryonic Stem Cell ... - December 13th, 2019
- BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program - Yahoo Finance - December 13th, 2019
- Exclusive: Two pigs engineered to have monkey cells born in China - New Scientist News - December 13th, 2019
- Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - P&T... - December 13th, 2019
- Aspen Neuroscience launches with $6.5M seed funding to develop personalized and autologous cell therapy for Parkinson's disease - TechStartups.com - December 13th, 2019
- Pig-Monkey Hybrid Chimeras Made By Scientists in China Dies! What is Chimera? Are There Human Chimeras? - LatestLY - December 13th, 2019
- Pig-Monkey Chimeras Have Been Brought to Term For The First Time - ScienceAlert - December 11th, 2019
- First Pig-Monkey Chimeras Were Just Created in China - Livescience.com - December 11th, 2019
- PHATED to be: Yale researchers give shape to big data - Yale News - December 11th, 2019
- Cell Harvesting Market a compound annual growth rate (CAGR) of 11.3% for the period of 2018-2023 - Crypto News Byte - December 11th, 2019
- Modulating the expression and activity of the potassium-chloride cotransporter KCC2 - SFARI News - November 26th, 2019
- Stem cells' role in medicine and research - The Medium - November 26th, 2019
- Stem Cell Assay Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2025 - The Denton... - November 26th, 2019
- Human Embryonic Stem Cells (HESC) Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 - Chronicles 360 - November 22nd, 2019
- Growing Organs in the Lab: One Step Closer to Reality - BioSpace - November 21st, 2019
- Major step taken in creating complex organs in the lab - Drug Target Review - November 21st, 2019
- Cell Therapy Aims To Improve Memory and Prevent Seizures Following Traumatic Brain Injury - Technology Networks - November 21st, 2019
- WCM-Q explores law and ethics of stem cells and AI in medicine - The Peninsula Qatar - November 18th, 2019
- Qatar- WCM-Q explores law and ethics of stem cells and AI in medicine - MENAFN.COM - November 18th, 2019
- New cell therapy improves memory and stops seizures after brain injury - Drug Target Review - November 18th, 2019
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Markets Gazette 24 - November 11th, 2019
- Global Stem Cell Assay Market 2019 Size, Share, Growth, Trends, Type, Application, Analysis and Forecast by 2026 - Markets Gazette 24 - November 11th, 2019
- Oct4, Considered Vital for Creating iPSCs, Actually Isnt Needed - The Scientist - November 8th, 2019
- A winding romp through advances in cell biology pushes readers to ponder the boundaries of life - Science Magazine - October 31st, 2019
- Cell Banking Outsourcing Market to 2027 - Global Analysis and Forecasts By Product Type (Cord Cell Banking, Adult Stem Cell Banking, Embryonic Stem... - October 31st, 2019
- Cell Isolation Market ||Becton, Dickinson, and Company, Thermo Fisher Scientific, Inc., Merck KGaA - Industry News Info - October 31st, 2019
- Scientists Made Mice Live 12% Longer by Hacking Their Telomeres - Futurism - October 22nd, 2019
- Scientists extend mice lifespan 12% by tweaking telomeres - Big Think - October 22nd, 2019
- Merck KGaA opens Shanghai Innovation Center and invests $ 14 million in the China Seed Fund - asume tech - October 19th, 2019
- Health policy will be the focus of the HLTH - asume tech - October 19th, 2019
- Syros sees strategic shift after the failure of the previously promising cancer drug - asume tech - October 19th, 2019
- What Theranos Whistleblowers Learn About Ethics in Health Startups - asume tech - October 19th, 2019
- Assessments of Treatment Options for Age-related Macular Degeneration - DocWire News - October 15th, 2019
- Stem Cells Market Growth Rate, Production Volume and Future Opportunities From 2019-2024 - Exponent Online - October 15th, 2019
- Catholics more motivated to donate if ethical investing is assured - Crux: Covering all things Catholic - October 10th, 2019
- Greenwood to step down as CEO of BIO after 2020 election - FierceBiotech - October 10th, 2019
- Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1 - Science Advances - October 10th, 2019
- Interview with Tamer Mohamed of Aspect Biosystems on Advancing Tissue Therapeutics - 3DPrint.com - October 10th, 2019
- Yale researchers develop way to help brain organoids thrive - Yale News - October 9th, 2019
- Catholics more motivated to donate if ethical investing is assured - The Catholic Spirit - October 9th, 2019
- Stem Cell Market: By Key Players, Market Competitive Landscape, Trends and Forecasts to 2024 - Joliet Observer - October 9th, 2019
- Stem Cell Therapy Market to Witness a Pronounce Growth During 2020 - Gem Newz - October 9th, 2019
- On creativity, plasticity and repentance - Arutz Sheva - October 5th, 2019
- What's in the cards for this year's Nobel Prizes? - STAT - October 2nd, 2019
- Moving beyond hype: Could one-two treatment restore damaged heart muscle? - University of Wisconsin-Madison - September 28th, 2019
- Conjugated polymers optically regulate the fate of endothelial colony-forming cells - Science Advances - September 28th, 2019
- God of miniscule things - Pune Mirror - September 27th, 2019
- New study shows insight into how cells maintain their identity - Drug Target Review - September 24th, 2019
- Human Embryonic Stem Cells Market: Expansion Strategies Set to Generate Substantial Revenue in the near Future - Rapid News Network - September 24th, 2019
- Global Stem Cells Market 2019 Strategic Assessment by Top Players CCBC, Vcanbio, Boyalife, Beikebiotech - News Coed - September 24th, 2019
- Study Gives Clues to the Origin of Huntington's Disease, and a New Way to Find Drugs - Nature World News - September 24th, 2019
- Global Stem Cells Market 2019 Business Statistics Focus Report Growth by Top Key Players CCBC, Vcanbio, Boyalife, Beikebiotec - The Industry News... - September 24th, 2019
- Orthopedic Biomaterials Product Market Set to Witness YoY Growth by 2018-2026 - NewsStoner - September 24th, 2019
- Global Fetal Bovine Serum Market : Industry Analysis and Forecast (2017-2026) - OnYourDesks - September 24th, 2019
- Stem Cell Therapy Market to Discern Steadfast Expansion During 2020 - Technology Trend - September 24th, 2019
- Embryonic Stem Cell - an overview | ScienceDirect Topics - May 22nd, 2019
- Embryonic Stem Cell Research and Vaccines using Fetal Tissue - May 6th, 2019
- Embryonic Stem Cells - Definitions, Use, and Research - April 28th, 2019
- Will Embryonic Stem Cells Ever Cure Anything? - MIT ... - April 28th, 2019
- Creating Embryonic Stem Cells Without Embryo Destruction - April 23rd, 2019
- What Are Stem Cells? - livescience.com - April 19th, 2019
- Embryonic Stem-Cell Research Reaches Moral, Medical Dead End - April 8th, 2019
- Embryonic Stem Cell: Definition, Uses and Collection ... - April 2nd, 2019
- Advantages of Embryonic Stem Cell Research | Sciencing - March 30th, 2019
- Obama Ends Stem Cell Research Ban - CBS News - March 10th, 2019
- Types of Stem Cells A Closer Look at Stem Cells - January 26th, 2019
- Embryonic Stem Cell Research - rtlofneo.com - December 19th, 2018
- The Ethics Of Embryonic Stem Cell Research Viewpoint Essay - December 11th, 2018
- Embryonic Stem Cells and Artificial Stem Cells Are ... - December 5th, 2018
- Embryonic stem cells | Cells | MCAT | Khan Academy - November 25th, 2018
- Crucial Differences Between Non-Embryonic and Embryonic Stem ... - November 23rd, 2018
- 14 Key Pros and Cons of Embryonic Stem Cell Research ... - November 5th, 2018
- Human Embryonic Stem Cells in Development, Volume 129 ... - September 29th, 2018
- Reprogrammed stem cells identical to embryonic stem cells - September 29th, 2018
- Embryonic Stem Cell Protocols by Kursad Turksen | Waterstones - September 29th, 2018
- What Are Stem Cells? Research, Transplant, Therapy, Definition - July 17th, 2018
- Embryonic Stem Cell Research Pros and Cons | HRFnd - June 19th, 2018
- Stem Cell Research: Is It in Danger? - September 29th, 2017
- Truth About Embryonic Stem Cells | Stem Cell Orthopedic ... - September 29th, 2017